Background
==========

Polypharmacy has become an emerging public health issue in recent years. Polypharmacy has been correlated with adverse drug reactions (ADRs), increased risk of hospitalization, reduced adherence to medication, and unnecessary expenses \[[@B1],[@B2]\]. In addition, several studies have indicated that polypharmacy is directly or indirectly associated with acute renal failure (ARF) \[[@B3]-[@B7]\]. Because the mortality rate of patients hospitalized for ARF is approximately 45 %, and almost 30 % of patients with ARF require renal transplantation \[[@B8]\], further assessments of the association between ARF and polypharmacy would be important in clinical practice.

Methodological problems are present in studies of the relationship between polypharmacy and ARF. First, the definition and measurement of polypharmacy are inconsistent \[[@B9]-[@B13]\], making comparisons among studies difficult. For example, polypharmacy has been defined as the concomitant use of five or more drugs, or as the number of unnecessary or inappropriate medications \[[@B14]-[@B16]\], with the former definition more widely used by physicians because of its clinical convenience \[[@B17]\]. Second, most previous studies of the association between polypharmacy and ARF have focused only on elderly people, not on the general population \[[@B3],[@B5],[@B8],[@B11],[@B14],[@B15],[@B17]\], thus making the results of these studies difficult to compare across different ages. Third, the involvement of managed care has resulted in fewer patients with polypharmacy, because drug benefit plans of managed care programs vary greatly \[[@B17]\]. Therefore, assessments of the association between polypharmacy and ARF require better health care environments to minimize these interfering factors.

Our aim of this study is to assess the association between the duration of polypharnacy and the development of ARF by analyzing the Taiwan National Health Insurance Research Database (NHIRD). The National Health Insurance (NHI) of Taiwan, first established in 1995, the NHI is a nationwide, compulsory, uniform and comprehensive health insurance system, in which every citizen (beneficiary) is covered by the same health benefits, including a full drug benefit package, excluded over-the-counter (OTC) drugs, in western and Chinese traditional medicine, regardless of the premium paid. Each citizen has access to any doctor or healthcare institution throughout the country, with same and low cost-sharing and/or deductibles. In addition, the NHI has contracts with over 92 % of all clinics and almost 100 % of all hospitals and other healthcare institutions, which have been accredited by standards very similar to those of the Joint Commission International (JCI). The low cost-sharing, similar quality and high accessibility of medical care have resulted in an average of 15.1 outpatient visits per person per year. Each individual receives about 3.35 medications per prescription, much higher than in European countries or the United States. These characteristics make possible a determination of the association between duration of polypharmacy and ARF \[[@B18],[@B19]\]. In addition, the NHIRD contains aggregated utilization records on all individuals throughout the country, including reasons for utilization in ICD-9-CM diagnostic codes and the medication details of each enrollee. This information allowed a determination of the factors influencing ARF, including gender, age, comorbidities, stay in intensive units (ICUs) and major site of operation one month prior to ARF admission, while assessing the association between duration of polypharmacy and ARF.

Methods
=======

Database and study design
-------------------------

This retrospective case--control study utilized data obtained from the 2003--2006 NHIRD, which enrolled nearly all 23 million people in Taiwan. The NHIRD, released annually to the public, contains all claim records, including encrypted personal identification number, gender, age, five diagnoses and five treatments(procedure or operation) in ICD-9-CM (International Classification of Disease, Clinical Modification, 9^th^ version) codes, types of lab tests, examinations, medications (in Anatomical Therapeutic Chemical codes), encrypted health institution code, encrypted physician identification and all expenditures for inpatient, outpatient, and emergency department (ED) services. Approval to analyze NHIRD data was obtained from the Ministry of Health, Taiwan (No. 1001460109).

The case group was selected from hospitalized patients diagnosed with ARF (ICD-9-CM: 584) \[[@B20]-[@B23]\] for the first time in 2006, with neither inpatient nor outpatient histories of ARF within the previous 3 years; none of these patients had been admitted due to trauma, surgery, burns, car accident, transplant, or infectious diseases. The control group was selected from patients hospitalized in 2006 but without ARF. None of the control patients had an inpatient or outpatient history of ARF within the previous 3 years. Subjects in the control group were matched 1:4 with those in the case group by MDC (major diagnosis category), hospital accreditation level (medical center, regional hospital and community hospital) and month of hospitalization. The case group included 20,790 patients and the control group included 83,160 patients (total, 103,950 patients).

Study variables
---------------

To investigate the association between the duration of polypharmacy and ARF, we retrospectively collected the medication history of all patients for 1 year prior to hospitalization. The duration of polypharmacy was defined as the summation of days a patient took more than 5 prescription medications on a single day in one year. These patients were further subdivided into those who took polypharmacy for less than 30, 31--90, 91--180, and over 181 days. The dependent variable was the occurrence of ARF (yes/no), whereas the control variables were those factors which were found by previous studies to have significant correlation with ARF, they included age, gender, having comorbidities when hospitalized for ARF, stay in ICUs during ARF hospitalization, site of operation for one month prior to ARF admission and number of days taking NSAID(Nonsteroidal anti-inflammatory drugs) or Triamterene. Age was classified into four categories: 0--18, 19--64, 65--79 and over 80 years. A comorbidity was defined as the diagnosis of and treatment with medication(s), as inpatient or outpatient for atherosclerotic heart diseases, congestive heart failure, cerebrovascular accident/transient ischemic attack, peripheral disease, other cardiac disease, chronic obstructive pulmonary disease, gastrointestinal bleeding, liver disease, dysrhythmia, cancer and diabetes; all of these comorbidities have been highly associated with failures in renal functions and have been used often in previous studies \[[@B24]\]. Stay in an ICU was classified as yes or no, depending on whether a patient had stayed in an ICU during the same hospitalization. Site of operation has also been found in previous studies as a factor correlated to ARF hospitalization \[[@B25]\]. In our study, site of operation was defined as having a primary operation (in ICD-9-CM OP codes) on the nervous system, endocrine system, eyes, ears, nose, mouth and pharynx, respiratory system, cardiovascular system, hemic and lymphatic system, digestive system, urinary system, male genital organs, female genital organs, musculoskeletal system, or integumentary system, or as obstetric or miscellaneous diagnostic and therapeutic procedures one month prior to ARF hospitalization. NSAID or Triamterene drugs were also found to be correlated to renal failure \[[@B26],[@B27]\]. Therefore, we also included number of days taking both classes of drugs as a control variable.

Statistical analysis
--------------------

Data were analyzed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). In the analysis of single dependent variables, we first used descriptive statistics to determine the distribution of age, gender, comorbidities, ICU and site of operation in patients with and without ARF and in patients with cumulative use of polypharmacy for less than 30, 31--90, 91--180, and over 181 days. *χ*^2^ and *t* tests were used to assess the association between the duration of polypharmacy and the occurrence of ARF and to investigate the variables that significantly affected ARF. Stepwise logistic regression analysis was utilized to determine the association between ARF and the duration of polypharmacy after controlling for patient variables.

Results
=======

The demographic and clinical characteristics of the case and control groups are shown in Table [1](#T1){ref-type="table"}. We found that ARF was significantly correlated with male gender (p\<0.001), with 59.23 % of patients with ARF being male. ARF also increased with age; of ARF patients, 0.84 % were aged 0--18 years, 31.78 % were aged 19--64 years, 38.63 % were aged 65--79 years and 28.75 % were over 80 years old. When the study samples were paired with hospital accreditation status, the results of χ^2^ tests were not significant. When we assessed the association between ARF and duration of polypharmacy, we found that a higher proportion of case than control patients received polypharmacy for 91--180 (16.14 % vs. 10.61 %) and for over 181 days (50.22 % vs. 24.12 %).

###### 

Descriptive statistics of subjects in case and control groups

                                                        **Control Group (N = 83,160)**   **Case Group (N = 20,790)**   **Crude odds ratio**   **p-value**           
  ----------------------------------------------------- -------------------------------- ----------------------------- ---------------------- ------------- ------- ---------
  Gender                                                                                                                                                            \<0.001
   Male                                                 44,695                           (53.75)                       12,314                 (59.23)       1.25     
   Female(ref)                                          38,465                           (46.25)                       8,476                  (40.77)                
  Age                                                                                                                                                               \<0.001
   0-18 years old (ref)                                 15,065                           (18.12)                       174                    (0.84)                 
   19-64 years old                                      39,199                           (47.14)                       6,607                  (31.78)       14.57    
   65-79 years old                                      19,684                           (23.67)                       8,032                  (38.63)       35.28    
   Over 80 years old                                    9,212                            (11.08)                       5,977                  (28.75)       56.10    
  Hospital accreditation status                                                                                                                                     N.A
   Medical center                                       33,544                           (40.34)                       8,386                  (40.34)                
   Regional hospital                                    35,240                           (42.38)                       8,810                  (42.38)                
   Community hospital                                   14,376                           (17.29)                       3,594                  (17.29)                
  Duration of polypharmacy                                                                                                                                          \<0.001
   Less than 30 days(ref)                               40,408                           (48.59)                       4,069                  (19.57)                
   31-90 days                                           13,867                           (16.68)                       2,925                  (14.07)       2.09     
   91-180 days                                          8,823                            (10.61)                       3,355                  (16.14)       3.78     
   Over 181 days                                        20,062                           (24.12)                       10,441                 (50.22)       5.17     
  ICU                                                                                                                                                               \<0.001
  Yes                                                   9,454                            (11.37)                       9,768                  (46.98)       6.91     
  NSAID~S~ or Triamterene day\*                         4.78                             (17.23)                       8.10                   (22.61)       1.01    \<0.001
  Comorbidity\*\*                                                                                                                                                    
  ASHD                                                  12,387                           (14.90)                       5,730                  (27.56)       2.17    \<0.001
  CHF                                                   5,876                            (7.07)                        4,711                  (22.66)       3.85    \<0.001
  CVA/TIA                                               9,181                            (11.04)                       5,289                  (25.44)       2.75    \<0.001
  PVD                                                   2,946                            (3.54)                        1,578                  (7.59)        2.24    \<0.001
  Other cardiac                                         5,641                            (6.78)                        2,538                  (12.21)       1.91    \<0.001
  COPD                                                  14,477                           (17.41)                       5,605                  (26.96)       1.75    \<0.001
  GI                                                    14,191                           (17.06)                       6,788                  (32.65)       2.36    \<0.001
  Liver disease                                         10,338                           (12.43)                       3,998                  (19.23)       1.68    \<0.001
  Dysrhythmia                                           5,783                            (6.95)                        3,952                  (14.20)       2.21    \<0.001
  Cancer                                                7,718                            (9.28)                        3,989                  (19.19)       2.32    \<0.001
  Diabetes                                              16,390                           (19.71)                       8,396                  (40.38)       2.76    \<0.001
  Site of operation                                                                                                                                                  
  Nervous system                                        1,564                            (1.88)                        285                    (1.37)        0.73    \<0.001
  Endocrine system                                      1,168                            (1.40)                        16                     (0.08)        0.05    \<0.001
  Eyes                                                  178                              (0.21)                        42                     (0.20)        0.95    0.736
  Ears                                                  79                               (0.09)                        6                      (0.03)        0.30    0.003
  Nose, mouth and pharynx                               668                              (0.80)                        67                     (0.32)        0.40    \<0.001
  Respiratory system                                    4,023                            (4.84)                        1,902                  (9.15)        1.98    \<0.001
  Cardiovascular system                                 7,465                            (8.89)                        5,165                  (24.84)       3.35    \<0.001
  Hemic and lymphatic system                            841                              (1.01)                        265                    (1.27)        1.26    0.001
  Digestive system                                      11,578                           (13.92)                       4,471                  (21.51)       1.69    \<0.001
  Urinary system                                        8,805                            (10.59)                       1,286                  (6.19)        0.56    \<0.001
  Male genital organs                                   71                               (0.09)                        4                      (0.02)        0.23    0.002
  Female genital organs                                 164                              (0.20)                        1                      (0.00)        0.03    \<0.001
  Obstetrical procedures                                0                                (0.00)                        0                      (0.00)        \-      \-
  Musculoskeletal system                                2,933                            (3.53)                        508                    (2.44)        0.69    \<0.001
  Integumentary system                                  2,218                            (2.67)                        626                    (3.01)        1.13    0.007
  Miscellaneous diagnostic and therapeutic procedures   27,814                           (33.45)                       12,863                 (61.87)       3.23    \<0.001

\* *t* test.

\*\*Abbreviations: ASHD, atherosclerotic heart disease; CHF, congestive heart failure;COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; GI, gastrointestinal bleeding; PVD, peripheral vascular disease.

Statistical analyses showed that all comorbidities tested were significantly correlated with ARF (p\<0.001), with all odds ratios being \>1.00. A higher percentage of patients in the case group stayed in the ICU during hospitalization (46.98 % vs. 11.37 %). Site of operation was significantly correlated with ARF (p\<0.001), except for operations on the ears (p\<0.736). The case group had significantly longer days in taking NSAID or Triamterene drugs than the control group (8.10 ± 22.61 days vs. 4.78 ± 17.23 days, p\<0.001).

Table [2](#T2){ref-type="table"} shows the results of a stepwise logistic regression analysis, in which ARF was the dependent variable, polypharmacy duration was the independent variable, and the influence of gender, age, ICU, comorbidities and site of operation were controlled. Compared with cases who received polypharmacy for less than 30 days, all other polypharmacy categories were at higher risks for ARF (p\<0.001), with the odds ratios (OR) increasing with increasing duration of polypharmacy, being 1.33, 1.65 and 1.74, in patients who received polypharmacy for 31--90, 91--180, and over 181 days, respectively. Males were 1.32 (p\<0.001) times more likely than females to develop ARF and increased age was also associated with ARF. Relative to patients aged 0--18 years old, those aged 19--65, 65--79, and over 80 years had ORs for the development of ARF of 6.40, 8.93 and 14.46, respectively. Stay in the ICU was also significantly associated with the development of ARF (OR 4.37; p\<0.001).

###### 

Stepwise logistic regression of the duration of polypharmacy and ARF

                                                        $\widehat{\beta}$   **SE(**$\widehat{\beta}$**)**   **Adjusted odds ratio**   **p-value**
  ----------------------------------------------------- ------------------- ------------------------------- ------------------------- -------------
  Duration of polypharmacy: Less than 30 days\*                                                                                       
   31- 90 days                                          0.28                0.03                            1.33                      \<0.001
   91 -- 180 days                                       0.50                0.03                            1.65                      \<0.001
   Over 181 days                                        0.55                0.03                            1.74                      \<0.001
  **Gender**:Female\*                                                                                                                  
  Male                                                  0.28                0.02                            1.32                      \<0.001
  **Age:**0-18 years old \*                                                                                                            
   19-64 years old                                      1.86                0.08                            6.40                      \<0.001
   65-79 years old                                      2.19                0.08                            8.93                      \<0.001
   Over 80 years old                                    2.67                0.08                            14.46                     \<0.001
  ICUs                                                  1.48                0.02                            4.37                      \<0.001
  Comorbidity                                                                                                                          
  ASHD                                                  −0.23               0.02                            0.80                      \<0.001
  CHF                                                   0.67                0.03                            1.95                      \<0.001
  CVA/TIA                                               0.21                0.02                            1.24                      \<0.001
  PVD                                                   0.14                0.04                            1.15                      0.001
  Other cardiac                                         0.08                0.03                            1.09                      0.006
  COPD                                                  −0.10               0.02                            0.91                      \<0.001
  GI                                                    0.30                0.02                            1.36                      \<0.001
  Liver disease                                         0.15                0.02                            1.16                      \<0.001
   Cancer                                               0.65                0.02                            1.92                      \<0.001
   Diabetes                                             0.46                0.02                            1.58                      \<0.001
  Site of operation                                                                                                                    
  Nervous system                                        −0.82               0.07                            0.44                      \<0.001
  Endocrine system                                      −2.25               0.26                            0.11                      \<0.001
  Nose, mouth and pharynx                               −0.58               0.14                            0.56                      \<0.001
  Respiratory system                                    −0.30               0.03                            0.75                      \<0.001
  Cardiovascular system                                 0.38                0.02                            1.47                      \<0.001
  Digestive system                                      0.26                0.02                            1.30                      \<0.001
  Urinary system                                        −0.21               0.03                            0.81                      \<0.001
  Male genital organs                                   −1.38               0.54                            0.25                      0.010
  Female genital organs                                 −2.63               1.01                            0.07                      0.009
  Musculoskeletal system                                −0.15               0.06                            0.86                      0.007
  Integumentary system                                  0.11                0.05                            1.12                      0.039
  Miscellaneous diagnostic and therapeutic procedures   0.35                0.02                            1.42                      \<0.001

\* reference group.

All comorbidities, except for atherosclerotic heart disease, dysarrhythmia and chronic obstructive pulmonary disease, were associated with higher risks of ARF (OR \>1.00 each; p\<0.001). Only surgical operations on the cardiovascular system, digestive system, integumentary system and miscellaneous diagnostic and therapeutic procedures showed ORs \>1.00 and with statistical significant (p\<0.05 each). In contrast, operations on the nervous system, endocrine system, nose, mouth and pharynx, respiratory system, urinary system, male genital organs, female genital organs and musculoskeletal system had a negative coefficient (between −2.63 and −0.15) compared with other sites of operation. Number of NSAID or Triamterene days was not selected to be included in the stepwise logistic regression model.

Discussion
==========

Our analysis of a dataset from the population-based NHIRD revealed a positive association between the duration of polypharmacy and the occurrence of ARF. Even after controlling for other factors, a longer duration of polypharmacy was associated with a higher risk of ARF.

The adoption of managed care systems by more countries has made research focusing on polypharmacy \[[@B17],[@B28]\], especially duration of polypharmacy, more difficult to perform. Usually the medications prescribed to enrollees in managed care programs are highly controlled, whereas non-prescription medications are not. The lack of information about non-prescription medications makes it very difficult to trace polypharmacy under managed care environments. The actual occurrence of polypharmacy may be higher than that reported, since many people do not inform their doctors about taking non-prescription drugs regularly. This situation, however, is rare in Taiwan, because the NHI pays for most drugs for acute and chronic diseases, and enrollees seldom spend their own money to buy nonprescription drugs regularly. It has made it easier to assess polypharmacy in Taiwan than in other countries. Moreover, since we defined polypharmacy as the concomitant use of more than five medications and we assessed the cumulative days of polypharmacy, we were better able to assess the duration of polypharmacy and the association of duration with ARF (or adverse drug events leading to ARF) than previous studies, which assessed only the correlation between polypharmacy and ARF \[[@B1],[@B2],[@B4],[@B7],[@B10],[@B29]-[@B31]\]. Indeed, we found that patients with a longer duration of polypharmacy were at higher risk for ARF hospitalization, consistent with previous findings reporting that excessive medication intake can cause renal damage and ARF \[[@B32]-[@B34]\]. Although we did not observe any significant differences between our case and control groups in the reasons for medication, we found that the average duration of polypharmacy was longer in the case than in the control group (191 days vs. 146 days). Therefore, the main cause of ARF may not be the medication itself, but rather the cumulative effects of polypharmacy. After controlling for confounding factors, including comorbidities, stay in the ICU during ARF hospitalization or site of operation within one month prior to ARF hospitalization, we still found that the risk of ARF was associated with duration of polypharmacy.

Consistent with previous reports, we found that polypharmacy was more likely to occur in elderly people \[[@B3],[@B9],[@B12]\]. The cumulative duration of polypharmacy in elderly people was likely higher because many of these individuals may take more than 5 medications per day due to multiple chronic diseases, including gastrointestinal bleeding, diabetes, chronic obstructive pulmonary disease and atherosclerotic heart disease. The optimal strategy to prevent ARF in elderly people may be to encourage doctors to avoid prescribing multiple medications or medications with renal toxicity to elderly people, or to prescribe medications at minimal doses \[[@B35]\]. This, however, may become more unrealistic since the elderly population in many countries is growing rapidly. Therefore, more research is necessary to reduce inappropriate medications in elderly patients requiring long duration of polypharmacy.

We also found that comorbidities, ICU stay during hospitalization for ARF and site of operation within one month prior to ARF hospitalization were associated with higher risks of ARF, findings consistent with previous reports \[[@B36],[@B37]\]. Our finding, however, that dysrhythmia was not associated with a risk of ARF, differed from those showing associations between cardiac diseases and ARF \[[@B38]-[@B40]\]. Our result may have been because of the inclusion of too many cardiac comorbidities in our logistic regression analysis. Although the number of days taking NSAID or Triamterene drugs was found significantly different between two groups, it was not selected in stepwise logistic regression model. It was probably because the number of days taking NSAID or triamterene drug was highly correlated with the duration of polyphamacy.

This study had two main limitations. First, we relied on medication claims in the NHIRD database to define polypharmacy. In reality, some patients may have purchased or taken medications on their own, thus underestimating the actual occurrence and duration of polypharmacy. However, due to the high accessibility of Taiwan's universal health insurance and the wide coverage for medications, few people would purchase medications on their own. Therefore, the influence of this underestimation on our results were likely minimal. Second, this study was limited by the use of this database, in that our case group included patients without a history of ARF for the previous three years, minimizing the effects of previous ARF on current ARF.

Conclusions
===========

We observed statistically significant associations between the duration of polypharmacy and the occurrence of ARF in this study. However, this association needs further study to ensure a causal relationship. In addition, the study of duration of polypharmacy also needs further attentions to specific group of people, such as elderly patients with multiple chronic diseases, since the society of many developed countries age very soon.
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